ArticleOncoimmunology2022
Bystander CD4
Article in Oncoimmunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 55 citations in OpenAlex.
- CD39 on CD8European journal of immunology · 2026Review
- Cell surface ADGRG1 and CD86 expression identifies antitumor CD4Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Adaptive resistance in cancer immunotherapy.Cellular & molecular immunology · 2026Review
- A 3D pooled PBMC-organoid co-culture platform for profiling immune susceptibility and PD-1 blockade response in gastric cancer.BMC medicine · 2026Article
- Oncolytic virotherapy mobilizes tumor-resident, granzyme B-producing bystander CD4Molecular therapy. Oncology · 2026Article
- Article
- Hallmarks and correlates of effective adoptive cell immunotherapy for cancer.Nature reviews. Immunology · 2026Review
- Single-cell TCR mapping reveals spatially coordinated T cell states in head and neck cancer.Science immunology · 2026Article
- PD-L1-Binding Antigen Presenters: Redirecting Vaccine-Induced Antibodies for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Oncolytic virotherapy potentiates chemo-PD-1 immunotherapy by engaging chemo-resistant bystander CD8Journal for immunotherapy of cancer · 2026Article
- From Immunobiology to Clinical Application: Tumor-Infiltrating Lymphocytes in Melanoma.Journal of personalized medicine · 2026Review
- A Framework for Comparing Mouse Neoantigen Immunogenicity.bioRxiv : the preprint server for biology · 2026Article
- CD39 and CD73: biological functions, diseases and therapy.Molecular biomedicine · 2025Review
- γδ T cells are the prime antitumoral T cells in pediatric neuroblastoma.Life science alliance · 2025Article
- CD4 T Cells Acquire Innate Capability Upon Classical T Cell Activation.European journal of immunology · 2025Article
- CD4Science immunology · 2024Article
- An oncolytic virus delivering tumor-irrelevant bystander T cell epitopes induces anti-tumor immunity and potentiates cancer immunotherapy.Nature cancer · 2024Article
- Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma.Nature reviews. Clinical oncology · 2024Review
- CD39 expression defines exhausted CD4Clinical & translational immunology · 2024Article
- Immune checkpoints are predominantly co-expressed by clonally expanded CD4Journal of experimental & clinical cancer research : CR · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-specific T cells likely underpin effective immune checkpoint-blockade therapies. Yet, most studies focus on Treg cells and CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.